AU4816497A - Receptor specific brain natriuretic peptide (bnp) - Google Patents

Receptor specific brain natriuretic peptide (bnp)

Info

Publication number
AU4816497A
AU4816497A AU48164/97A AU4816497A AU4816497A AU 4816497 A AU4816497 A AU 4816497A AU 48164/97 A AU48164/97 A AU 48164/97A AU 4816497 A AU4816497 A AU 4816497A AU 4816497 A AU4816497 A AU 4816497A
Authority
AU
Australia
Prior art keywords
bnp
natriuretic peptide
brain natriuretic
receptor specific
specific brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU48164/97A
Other languages
English (en)
Inventor
David G. Lowe
Jill R. Schoenfeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU4816497A publication Critical patent/AU4816497A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU48164/97A 1996-10-22 1997-10-09 Receptor specific brain natriuretic peptide (bnp) Abandoned AU4816497A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73188096A 1996-10-22 1996-10-22
US08731880 1996-10-22
PCT/US1997/018384 WO1998017690A1 (en) 1996-10-22 1997-10-09 Receptor specific brain natriuretic peptide (bnp)

Publications (1)

Publication Number Publication Date
AU4816497A true AU4816497A (en) 1998-05-15

Family

ID=24941306

Family Applications (1)

Application Number Title Priority Date Filing Date
AU48164/97A Abandoned AU4816497A (en) 1996-10-22 1997-10-09 Receptor specific brain natriuretic peptide (bnp)

Country Status (6)

Country Link
EP (1) EP0939770A1 (ja)
JP (1) JP2001503256A (ja)
AU (1) AU4816497A (ja)
CA (1) CA2269656A1 (ja)
WO (1) WO1998017690A1 (ja)
ZA (1) ZA979060B (ja)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG159387A1 (en) 2002-11-26 2010-03-30 Biocon Ltd In Modified natriuretic compounds, conjugates, and uses thereof
PL2348114T3 (pl) 2004-04-21 2019-08-30 Alexion Pharmaceuticals, Inc. Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość
AU2011350066A1 (en) 2010-12-27 2013-07-11 Alexion Pharma International Sarl Compositions comprising natriuretic peptides and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
CN107405390A (zh) 2014-12-05 2017-11-28 阿雷克森制药公司 用重组碱性磷酸酶治疗癫痫
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
WO2017031114A1 (en) 2015-08-17 2017-02-23 Alexion Pharmaceuticals, Inc. Manufacturing of alkaline phosphatases
EP3355904A4 (en) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. IDENTIFICATION OF EFFECTIVE DOSE SHEETS FOR TISSUE-SPECIFIC ALKALINE PHOSPHATASE ENZYMERSAT THERAPY OF HYPOPHOSPHATASIA
WO2017074466A1 (en) 2015-10-30 2017-05-04 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
EP3436052A4 (en) 2016-04-01 2019-10-09 Alexion Pharmaceuticals, Inc. TREATMENT OF MUSCLE WEAKNESS USING ALKALINE PHOSPHATASES
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
EP3464573A4 (en) 2016-06-06 2020-02-19 Alexion Pharmaceuticals, Inc. IMPACT OF METAL ON THE PRODUCTION OF ALKALINE PHOSPHATASES
WO2018035420A1 (en) 2016-08-18 2018-02-22 Alexion Pharmaceuticals, Inc. Methods for treating tracheobronchomalacia
BR112019020506A2 (pt) 2017-03-31 2020-08-04 Alexion Pharmaceuticals, Inc. métodos para o tratamento de hipofosfatasia (hpp) em adultos e adolescentes
EP3773684A1 (en) 2018-03-30 2021-02-17 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
BR112023016048A2 (pt) 2021-02-12 2023-11-14 Alexion Pharma Inc Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69432123T2 (de) * 1993-11-12 2004-01-08 Genentech, Inc., South San Francisco Rezeptor spezifische atrio-natriuretische peptide

Also Published As

Publication number Publication date
WO1998017690A1 (en) 1998-04-30
JP2001503256A (ja) 2001-03-13
ZA979060B (en) 1999-04-09
EP0939770A1 (en) 1999-09-08
CA2269656A1 (en) 1998-04-30

Similar Documents

Publication Publication Date Title
AU4816497A (en) Receptor specific brain natriuretic peptide (bnp)
KR20010012568A (ko) 펩타이드 부갑상선 호르몬 유사체 및 이를 포함하는 약제학적 조성물
AU6868398A (en) Mu-opiate receptor peptides
HUP9901455A3 (en) Somatostatin peptides
AU5850698A (en) Video sequence recognition
AU6996898A (en) Runway reservation system
AU7966098A (en) Hm74a receptor
GB9827348D0 (en) Natriuretic peptide
AU7576096A (en) Il-13 receptor polypeptide
AU7132898A (en) Edg-1-like receptor
AU6450196A (en) Hr-1 receptor
AU6692598A (en) Growth factor receptor binding protein
AU5412996A (en) Truncated igf-i
AU6175696A (en) Hr-1 receptor
AU6596096A (en) Calcitonin gene-related peptide receptor component factor (houdc44)
AU6820898A (en) Natriuretic peptide derivatives
AU3388597A (en) Human type ii gonadotropin-releasing hormone receptor
AU7165998A (en) Neurotrophic factor receptors
AU1688899A (en) Novel seven-pass transmembrane receptor protein
AU1999999A (en) Contryphan peptides
AU4753496A (en) Human g-protein coupled receptor
AUPO938697A0 (en) Novel receptor
AU4554493A (en) Interferon receptor binding peptides
AU7002594A (en) Dna coding for the human thyrotropin-releasing hormone receptor
AUPO957397A0 (en) Transporter protein